View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 11, 2020

Sanofi and GSK postpone Covid-19 vaccine trial to optimise candidate

By Allie Nawrat

Sanofi and GlaxoSmithKline (GSK) have decided to delay their Covid-19 vaccine programme because their adjuvanted recombinant protein vaccine failed to produce a sufficient immune response in older adults enrolled in a US Phase I/II trial.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

The two companies initiated the Phase I/II trial in September 2020; Sanofi and GSK hoped to be able to be start a Phase III study in December 2020 and then request regulatory approval in the first half of 2021.

However, because of the inadequate response to the vaccine in adults over 49, Sanofi and GSK have decided to refine the concentration of antigen in their vaccine. This means the pair need to push their Phase III study back to the second quarter of 2021 at the earliest, meaning regulatory approvals are not expected until the fourth quarter of 2021.

Simultaneous to announcing the delay, Sanofi and GSK published pre-clinical data from non-human primates that showed that an improved antigen formulation allowed the vaccine candidate to protect against lung pathology and lead to rapid viral clearance within four days.

Sanofi executive vice-president and head of its vaccine division Sanofi Pasteur Thomas Triomphe said: “We care greatly about public health which is why we are disappointed by the delay announced today, but all our decisions are and will always be driven by science and data.

“We have identified the path forward and remain confident and committed to bringing a safe and efficacious Covid-19 vaccine. Following these results and the latest encouraging new pre-clinical data, we will now work to further optimise our candidate to achieve this goal.”

GSK president of vaccines Roger Connor added: “The results of the study are not as we hoped. Based on previous experience and other collaborations, we are confident that GSK’s pandemic adjuvant system, when coupled with a Covid-19 antigen, can elicit a robust immune response with an acceptable reactogenicity profile.

“Our aim now is to work closely with our partner Sanofi to develop this vaccine, with an improved antigen formulation, for it to make a meaningful contribution to preventing Covid-19.”

Sanofi and GSK’s Covid-19 vaccine candidate leverages both companies’ established technology platforms, which have proven successful against influenza. Sanofi is providing the S protein Covid-19 antigen based on its recombinant DNA technology, while GSK is contributing its pandemic adjuvant technology.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology